NZ618740B2 - Anti-axl antibodies and uses thereof - Google Patents
Anti-axl antibodies and uses thereof Download PDFInfo
- Publication number
- NZ618740B2 NZ618740B2 NZ618740A NZ61874012A NZ618740B2 NZ 618740 B2 NZ618740 B2 NZ 618740B2 NZ 618740 A NZ618740 A NZ 618740A NZ 61874012 A NZ61874012 A NZ 61874012A NZ 618740 B2 NZ618740 B2 NZ 618740B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- seq
- axl
- axi
- antibodies
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 267
- 108090001123 antibodies Proteins 0.000 title claims abstract description 267
- 108010045030 monoclonal antibodies Proteins 0.000 claims abstract description 68
- 102000005614 monoclonal antibodies Human genes 0.000 claims abstract description 68
- 206010021425 Immune system disease Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 28
- 230000035693 Fab Effects 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 12
- 108091006028 chimera Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 5
- 206010027665 Immune disorder Diseases 0.000 claims description 5
- 206010047461 Viral infection Diseases 0.000 claims description 5
- 208000001756 Virus Disease Diseases 0.000 claims description 5
- 229940079593 drugs Drugs 0.000 claims description 5
- 230000001732 thrombotic Effects 0.000 claims description 5
- 206010060945 Bacterial infection Diseases 0.000 claims description 3
- 208000006551 Parasitic Disease Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims 2
- 210000004027 cells Anatomy 0.000 description 109
- 230000027455 binding Effects 0.000 description 60
- 241000699666 Mus <mouse, genus> Species 0.000 description 45
- 101710039535 AXL Proteins 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 40
- 101700018422 GAS6 Proteins 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 239000000427 antigen Substances 0.000 description 24
- 108091007172 antigens Proteins 0.000 description 24
- 102000038129 antigens Human genes 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 22
- 229960000060 monoclonal antibodies Drugs 0.000 description 22
- -1 polyethylene Polymers 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 238000004166 bioassay Methods 0.000 description 17
- 239000000611 antibody drug conjugate Substances 0.000 description 15
- 108091008116 antibody drug conjugates Proteins 0.000 description 15
- 230000003899 glycosylation Effects 0.000 description 15
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 108050009401 Fibronectin type III Proteins 0.000 description 13
- 102000002090 Fibronectin type III Human genes 0.000 description 13
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 201000002528 pancreatic cancer Diseases 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108010027440 Immunoconjugates Proteins 0.000 description 11
- 102000018748 Immunoconjugates Human genes 0.000 description 11
- 239000002254 cytotoxic agent Substances 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000006011 modification reaction Methods 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 230000000865 phosphorylative Effects 0.000 description 11
- 231100000599 cytotoxic agent Toxicity 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 101700006234 AKT1 Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 210000004102 animal cell Anatomy 0.000 description 8
- 108010044540 auristatin Proteins 0.000 description 8
- 230000000295 complement Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 240000005988 Colubrina elliptica Species 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 229940088598 Enzyme Drugs 0.000 description 7
- 230000036499 Half live Effects 0.000 description 7
- 102000018358 Immunoglobulins Human genes 0.000 description 7
- 108060003951 Immunoglobulins Proteins 0.000 description 7
- 101700058157 Mabi Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 101710039033 pkbA Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 230000001388 anti-tubulin Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004962 mammalian cells Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002285 radioactive Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 4
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 4
- 102000033147 ERVK-25 Human genes 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 4
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 108091005706 TAM receptors Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 4
- 229940020899 hematological Enzymes Drugs 0.000 description 4
- 230000002440 hepatic Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 3
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 102100004159 GAS6 Human genes 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 208000005017 Glioblastoma Diseases 0.000 description 3
- 210000004408 Hybridomas Anatomy 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 210000002307 Prostate Anatomy 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229930013930 alkaloids Natural products 0.000 description 3
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002797 proteolythic Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100001248 AKT1 Human genes 0.000 description 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 229940009098 Aspartate Drugs 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 229960002170 Azathioprine Drugs 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229950009017 Cemadotin Drugs 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 2
- 230000036947 Dissociation constant Effects 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N Dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 102100010813 EGF Human genes 0.000 description 2
- 101700033006 EGF Proteins 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- XOPYFXBZMVTEJF-PDACKIITSA-N Eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N Epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-TYFQHMATSA-N Epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229960001842 Estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 101700044513 FUT8 Proteins 0.000 description 2
- 102100012684 FUT8 Human genes 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101710037135 GAPC2 Proteins 0.000 description 2
- 101710037116 GAPC3 Proteins 0.000 description 2
- 101710025049 GAPDG Proteins 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 102100006425 GAPDH Human genes 0.000 description 2
- 101710010461 Gapdh1 Proteins 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710025050 MK0970 Proteins 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000009905 Neurofibromatosis Diseases 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000491 Small cell lung cancer Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N aldehydo-D-arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 101710025091 cbbGC Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 108010046713 cemadotin Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 201000011231 colorectal cancer Diseases 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001085 cytostatic Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002357 endometrial Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 229930013357 epothilone A Natural products 0.000 description 2
- 229930013349 epothilone B Natural products 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 101710025070 gapdh-2 Proteins 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002489 hematologic Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000003463 hyperproliferative Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000000984 immunochemical Effects 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 101700027776 mab-3 Proteins 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 101700074470 pac Proteins 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 235000013533 rum Nutrition 0.000 description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5S,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- CWODDUGJZSCNGB-HQNRRURTSA-N (E,2S,3R,5R,8R,9S)-10-[(2R,3R,4R,5S,6R)-6-[(1S,2R,3S,4S,5R,11S)-12-[(1R,3S,5S,7R)-5-[(8S)-9-[(2R,3R,4R,5R,6S)-6-[(E,2S,3S,6S,9R,10R)-10-[(2S,4R,5S,6R)-6-[(2R,3R)-4-[(2R,3S,4R,5R,6S)-6-[(2S,3Z,5E,8R,9S,10R,12Z,17S,18R,19R,20R)-21-[(2R,3R,4R,5S,6R)-6-[(Z,3R Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CCCCC[C@H](C)C[C@@H]2[C@@]3(C)C[C@H](C)C[C@@](O3)(CCCCCCC[C@H](O)C[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@](O)(C[C@H](O)[C@@H](C)\C=C\[C@@H](O)CC[C@@H](O)[C@@H](O)[C@H]4O[C@H](C[C@@H](O)[C@H](O)C[C@@H]5[C@H]([C@H](O)[C@@H](O)[C@H](C[C@H](O)\C=C/C=C/C[C@@H](O)[C@H](O)[C@H](O)C\C=C/C(=C)CC[C@H](O)[C@@H](O)[C@H](O)[C@H](C)C[C@@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](\C=C/[C@@H](O)[C@H](O)C[C@H]7O[C@H]8C[C@H](O[C@@H]8CC[C@@H]8[C@@H](C[C@@H](CN)O8)O)C7)O6)O)O5)O)[C@@H](O)[C@H](O)C4)O3)O)O2)[C@H](C[C@H](O)[C@H](O)C(\C)=C\[C@H](O)C[C@@H](C)[C@H](O)C(=O)N\C=C\C(=O)NCCCO)[C@H](O)[C@@H](O)[C@@H]1O CWODDUGJZSCNGB-HQNRRURTSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- PBSPQZHJEDTHTL-UHFFFAOYSA-N 2-benzoylpentanoic acid Chemical compound CCCC(C(O)=O)C(=O)C1=CC=CC=C1 PBSPQZHJEDTHTL-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-Aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- 108010007562 Adalimumab Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 Amantadine Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- 101700047412 CCNO Proteins 0.000 description 1
- 102100003755 CCNO Human genes 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 210000004507 Chromosomes, Artificial Anatomy 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 108010009858 Echinomycin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 231100000776 Exotoxin Toxicity 0.000 description 1
- 102100008658 FN1 Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N Fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940020967 Gemzar Drugs 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- IUAYMJGZBVDSGL-UHFFFAOYSA-N Gramicidin Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 IUAYMJGZBVDSGL-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 229940048921 Humira Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 108010053490 Infliximab Proteins 0.000 description 1
- 241000283162 Inia geoffrensis Species 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- AUJXLBOHYWTPFV-CVLRASHMSA-N N-[(1R,4R,7R,11S,14R,17R,20R,24S)-2,4,12,15,17,25-hexamethyl-29-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-7-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-20-yl]quinoxaline-2-carbo Chemical compound C([C@H](C(=O)N[C@H](C)C(=O)N1C)NC(=O)C=2N=C3C=CC=CC3=NC=2)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CSC2SC AUJXLBOHYWTPFV-CVLRASHMSA-N 0.000 description 1
- 108010035649 Natalizumab Proteins 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- IDBIFFKSXLYUOT-UHFFFAOYSA-N Netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 1
- 108020001162 Nitroreductases Proteins 0.000 description 1
- 102000004459 Nitroreductases Human genes 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 102100000264 PROS1 Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N Phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940116176 Remicade Drugs 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960000329 Ribavirin Drugs 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 101000551167 TTN Proteins 0.000 description 1
- 101710002875 TYRO3 Proteins 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 Trifluridine Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229960004799 Tryptophan Drugs 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 229940079023 Tysabri Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 241000912169 Ufo Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 210000003501 Vero Cells Anatomy 0.000 description 1
- 229960003636 Vidarabine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 108091005597 Vitamin K-dependent proteins Proteins 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 Zidovudine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical class C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- DIOLOCSXUMYFJN-UHFFFAOYSA-O azanium;calcium Chemical compound [NH4+].[Ca+2] DIOLOCSXUMYFJN-UHFFFAOYSA-O 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 235000018185 birch Nutrition 0.000 description 1
- 235000018212 birch Nutrition 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 101700075078 cbpG Proteins 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019876 cocoa butter improver Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000000445 cytocidal Effects 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 102000027117 human TTN protein Human genes 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005291 magnetic Effects 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- RMHMCAVBXYSACO-UHFFFAOYSA-M octadecanoyloxyaluminum Chemical compound [Al+].CCCCCCCCCCCCCCCCCC([O-])=O RMHMCAVBXYSACO-UHFFFAOYSA-M 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000575 proteomic Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000001296 transplacental Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- ZTHWFVSEMLMLKT-CAMOTBBTSA-N vidarabine monohydrate Chemical compound O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O ZTHWFVSEMLMLKT-CAMOTBBTSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N γ-carboxy-L-glutamic acid zwitterion Chemical group OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Abstract
Disclosed is a monoclonal antibody having specificity for Axl that binds to the FN3 regions of domains 1 and 2 of Axl, comprising the CDRs of the sequences as disclosed in the specification. Also disclosed is the use of the antibody in treating immune diseases.
Description
ANTI-AXL ANTIBODIES AND USES THEREOF
FIELD OF THE INVENTION:
The present invention relates to anti-Axi antibodies and uses thereof in diagnostic and
therapeutic methods.
BACKGROUND OF THE INVENTION:
Axi belongs to the TAM subfamily of receptor tyrosine kinases (RTKs) that also
includes Tyro3 and Mer. The TAM receptors are characterized by a combination of two
immunoglobin- like domains and dual flbronectin type HI repeats in the extracellular region
and a cytoplasmic kinase domain. The ligands for TAM receptors are Gas6 (growth-arrest-
specific 6) and protein S, two vitamin-K dependent proteins that show 43% amino acid
sequence identity and share similar domain structures. Each protein has an N-terminal GIa
domain containing 11 g-carboxyglutamic acid residues, followed by four epidermal growth
factor (EGF)-like modules, and a C-terminal sex hormone-binding globlin (SHBG)-like
structure consisting of two tandem laminin G domains. The SHBG domain is both necessary
and sufficient for TAM receptor binding and activation, whereas the GIa domain binds the
negatively charged membrane phospholipids and plays an important role in TAM-mediated
phagocytosis of apoptotic cells. TAM activation and signalling has been implicated in
multiple cellular responses including cell survival, proliferation, migration and adhesion.
Dysregulation of Axi or its ligand Gas6 is implicated in the pathogenesis of a variety
of human cancers. Overexpression of AxI has been reported in a wide array of human cancers
(lung, prostate, breast, gastric, pancreatic, ovarian, thyroid, blood cancers, renal cell
carcinoma as well as glioblastoma ... ) and is associated with invasiveness, metastasis and
negative prognosis. These findings suggest that Axi may be involved in the regulation of
multiple aspects of tumorigenesis including tumor growth, invasion and angiogenesis and thus
represents a target for therapeutic intervention in cancer especially for the development of
anti-metastatic cancer therapy and for other multiple cancer treatment including treatment of
drug resistance.
Accordingly, anti-Axi monoclonal antibodies have been described for use in the
treatment of cancers. For example publications relating to anti-Axi antibodies include
W02009/063965, W02009/062690, and W02011/014457.
Other roles of Axi dependent or not of its ligands such as inhibition of immune
functions, activation of platelet aggregation and viral infection inducer (as an example, Ebola
and Lassa virus uptake is promoted by Axi) highlight the potential of Axi as therapeutic target
for other applications than oncology.
SUMMARY OF THE INVENTION:
The present invention relates to a monoclonal antibody having specificity for Axl,
comprising an heavy chain variable region comprising SEQ ID NO;2 in the H-CDRI region,
SEQ ID NO:3 in the H-CDR2 region and NO:4 in the U-CDR3 region ; and a light
SEQ ID
SEQ ID NO:7 in the
chain variable region comprising SEQ ID NO:6 in the L-CDRI region,
L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to
the extracellular domain of Axi via, SEQ IDNO:9 and SEQ ID NO: 10,
According to an aspect of the present invention, there is provided an antibody
having specificity for Ax 1, wherein said antibody binds to a conformational epitope of Ax 1
comprising the peptide of SEQ ID NO:9 in the FN3 domain 1 of Axi and the peptide of
SEQ ID NO: 10 in the FN3 domain 2 of Axi.
According to another aspect, the present invention provides use of a monoclonal
antibody having specificity for a monoclonal antibody having specificity for Axl
comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1
region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region;
and a light chain variable region comprising SEQ ID NO:6 in the L-CDR1 region, SEQ ID
NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region; or a fragment
thereof which is selected from the group consisting of Fv, Fab, F(ab’)2, Fab’, dsFv, scFv,
sc(Fv)2 and diabodies, in the manufacture of a medicament for the treatment of cancer.
According to a further aspect, the present invention provides use of a monoclonal
antibody having specificity a monoclonal antibody having specificity for Axl comprising
an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID
NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain
variable region comprising SEQ ID NO:6 in the L-CDR1 region, SEQ ID NO:7 in the L-
CDR2 region and SEQ ID NO:8 in the L-CDR3 region; or a fragment thereof which is
selected from the group consisting of Fv, Fab, F(ab’)2, Fab’, dsFv, scFv, sc(Fv)2 and
diabodies, in the manufacture of a medicament for the treatment of a disease selected from
10001194
the group consisting of human immune disorders, thrombotic diseases, cardiovascular
diseases and viral, bacterial, or parasitic infections in a subject in need thereof.
DETAILED DESCRIPTION OF THE INVENTION:
Definitions:
The term "Ax!" has its general meaning in the art and refers to the human Axl. Axi is
also known as "Ark", ’Tyro-7", "ufo", or "jtkl 1".
The term "anti-Ax! antibody" refers to an antibody directed against Axi.
According to the present invention, "antibody" or "immunoglobuliri" have the same
meaning, and will be used equally in the present invention. The term "antibody" as used
herein refers to immunoglobulin molecules and immunologically active portions of
immunoglobulin molecules, i.e., molecules that contain an antigen binding site that
immunospecifically binds an antigen. As such, the term antibody encompasses not only whole
antibody molecules, but also antibody fragments as well as variants (including derivatives) of
antibodies and antibody fragments. In natural antibodies, two heavy chains are linked to each
other by disulfidc bonds and each heavy chain is linked to a light chain by a disulfide bond.
There are two types of light chain, lambda (1) and kappa (k). There are five main heavy chain
classes (or isotypes) which determine the functional activity of an antibody molecule: 1gM,
IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains. The light chain
includes two domains, a variable domain (VL) and a constant domain (CL). The heavy chain
includes four domains, a variable domain (VH) and three constant domains (CHI, CH2 and
CH3, collectively referred to as CT-I). The variable regions of both light (VL) and heavy (VH)
10001194
chains determine binding recognition and specificity to the antigen. The constant region
domains of the light (CL) and heavy (CH) chains confer important biological properties such
as antibody chain association, secretion, trans-placental mobility, complement binding, and
binding to Fc receptors (FcR). The Fv fragment is the N-terminal part of the Fab fragment of
an immunoglobulin and consists of the variable portions of one light chain and one heavy
chain. The specificity of the antibody resides in the structural complementarity between the
antibody combining site and the antigenic determinant. Antibody combining sites are made up
of residues that are primarily from the hypervariable or complementarity determining regions
(CDRs). Occasionally, residues from nonhypervariable or framework regions (FR) influence
the overall domain structure and hence the combining site. Complementarity Determining
Regions or CDRs refer to amino acid sequences which together define the binding affinity
and specificity of the natural Fv region of a native immunoglobulin binding site. The light and
heavy chains of an immunoglobulin each have three CDRs, designated L-CDR1, L-CDR2, L-
CDR3 and H-CDR1, H-CDR2, H-CDR3, respectively. An antigen-binding site, therefore,
includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region.
Framework Regions (FR5) refer to amino acid sequences interposed between CDRs.
The term "chimeric antibody" refers to an antibody which comprises a VH domain and
a VL domain of an antibody derived the 3E3E8 antibody, and a CH domain and a CL domain
of a human antibody.
According to the invention, the term "humanized antibody" refers to an antibody
having variable region framework and constant regions from a human antibody but retains the
CDRs of the 3E3E8 antibody.
The term "Fab" denotes an antibody fragment having a molecular weight of about
50,000 and antigen binding activity, in which about a half of the N-terminal side of H chain
and the entire L chain, among fragments obtained by treating IgG with a protease, papaine,
are bound together through a disulfide bond.
The term "F(ab’)2" refers to an antibody fragment having a molecular weight of about
100,000 and antigen binding activity, which is slightly larger than the Fab bound via a
disulfide bond of the hinge region, among fragments obtained by treating IgG with a protease,
pepsin.
The term "Fab’ " refers to an antibody fragment having a molecular weight of about
50,000 and antigen binding activity, which is obtained by cutting a disulfide bond of the hinge
region of the F(ab’)2.
A single chain Fv ("scFv") polypeptide is a covalently linked VH::VL heterodimer
which is usually expressed from a gene fusion including VH and VL encoding genes linked
by a peptide-encoding linker. "dsFv" is a VH::VL heterodimer stabilised by a disulfide bond.
Divalent and multivalent antibody fragments can form either spontaneously by association of
monovalent scFvs, or can be generated by coupling monovalent scFvs by a peptide linker,
such as divalent sc(Fv)2.
The term "diabodies" refers to small antibody fragments with two antigen-binding
sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-
chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is
too short to allow pairing between the two domains on the same chain, the domains are forced
to pair with the complementary domains of another chain and create two antigen-binding
sites.
By "purified" and "isolated" it is meant, when referring to an antibody according to the
invention or to a nucleotide sequence, that the indicated molecule is present in the substantial
absence of other biological macromolecules of the same type. The term "purified" as used
herein preferably means at least by weight, more preferably at least 85% by weight,
more preferably still at least 95% by weight, and most preferably at least 98% by weight, of
biological macromolecules of the same type are present. An "isolated" nucleic acid molecule
which encodes a particular polypeptide refers to a nucleic acid molecule which is
substantially free of other nucleic acid molecules that do not encode the polypeptide;
however, the molecule may include some additional bases or moieties which do not
deleteriously affect the basic characteristics of the composition.
Antibodies of the invention:
The present invention provides for isolated anti-AxI antibodies or fragments thereof.
In particular, the inventors have raised a murine anti-Axl antibody (3E3E8) producing
hybridoma. The inventors have cloned and characterized the variable domain of the light and
heavy chains of said mAb 3E3E8, and thus determined the complementary determining
regions (CDRs) domain of said antibody as described in Table 1:
mAb 3E3E8 Sequence
Domains
VH QVQLKESGPGLVAPSQSLSITCSVSGFSLTNYAVHWVRQPPGKGLE
WLGVIWAGGSTNYNSALMSRLPJSKDNSKSQVFFKMSLQTDDTA
MYYCARYYGSSLYPMDYWGQGTSVTVSS (SEQ ID NO: 1)
H-CDR1 NYAVH (SEQ ID NO: 2)
H-CDR2 VIWAGGSTNYNSALMS (SEQ ID NO:3)
H-CDR3 YYGSSLYPMDY (SEQ ID NO:4)
VL DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPG
QSPQLLIYRMSNLASGVPDRFSGSGSGTVFTLRISGVEAEDVGVYY
CMQHLEYPWTFGGGTELEIK (SEQ ID NO:5)
(SEQ ID NO: 6)
L-CDR1 RSSKSLLHSNGNTYLY
L-CDR2 RMSNLA (SEQ ID NO: 7)
L-CDR3 MQHLEYPWT (SEQ ID NO:8)
Therefore, the invention relates to a monoclonal antibody having specificity for Axi,
comprising a heavy chain wherein the variable domain comprises at least one CDR having a
sequence selected from the group consisting of SEQ ID NO:2 for H-CDR1, SEQ ID NO:3 for
H-CDR2 and SEQ ID NO:4 for H-CDR3.
The invention also relates to a monoclonal antibody having specificity for Axi,
comprising a light chain wherein the variable domain comprises at least one CDR having a
for L-CDRI, SEQ ID NO:7 for
sequence selected from the group consisting of SEQ ID NO:6
L-CDR2 and SEQ ID NO:8 for L-CDR3.
The monoclonal antibody of the invention, may comprise a heavy chain wherein the
variable domain comprises at least one CDR having a sequence selected from the group
consisting of SEQ ID NO:2 for H-CDR1, SEQ ID NO:3 for H-CDR2 and SEQ ID NO:4 for
H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a
SEQ ID NO:7
sequence selected from the group consisting of SEQ ID NO:6 for L-CDR1,
L-CDR2 and SEQ ID NO: 8 for L-CDR3.
In particular, the invention provides an anti-AxI monoclonal antibody comprising:
an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1
region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-
CDR3 region; and
- a light chain variable region comprising SEQ ID NO:6 in the L-CDR1 region,
SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3
region.
In a particular embodiment, the heavy chain variable region of said antibody has the
amino acid sequence set forth as SEQ ID NO: 1 and/or the light chain variable region has the
amino acid sequence set forth as SEQ ID NO: 5.
In another embodiment, the monoclonal antibody of the invention is a chimeric
antibody, preferably a chimeric mouse/human antibody. In particular, said mouse/human
chimeric antibody may comprise the variable domains of 3E3E8 antibody as defined above.
In another embodiment, the monoclonal of the invention is a humanized antibody. In
particular, in said humanized antibody, the variable domain comprises human acceptor
frameworks regions, and optionally human constant domain where present, and non-human
donor CDRs, such as mouse CDRs as defined above.
The invention further provides anti-Axi fragments directed against Axl of said
antibodies which include but are not limited to Fv, Fab, F(ab’)2, Fab’, dsFv, scFv, sc(Fv)2
and diabodies.
The invention further provides anti-Axl antibody or fragments that bind to amino acid
in the extracellular part of Ax!.
sequences SEQ ID NO:9 and SEQ ID NO:
mAb 3E3E8 Human Axi sequence (epitope)
FN3 domain 1 NLHLVSR (SEQ ID NO:9)
(SEQ ID NO:lO)
FN3 domain 2 VLMDIGLRQEVTLE
In another aspect, the invention relates to a polypeptide which has a sequence selected
from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,
SEQ ID SEQ ID NO: 6; SEQ ID NO:7 and SEQ ID NO:8.
NO:5;
Methods of producing antibodies of the invention:
Anti-AxI antibodies of the invention may be produced by any technique known in the
art, such as, without limitation, any chemical, biological, genetic or enzymatic technique,
either alone or in combination.
Knowing the amino acid sequence of the desired sequence, one skilled in the art can
readily produce said antibodies, by standard techniques for production of polypeptides. For
instance, they can be synthesized using well-known solid phase method, preferably using a
commercially available peptide synthesis apparatus (such as that made by Applied
Biosystems, Foster City, California) and following the manufacturer’s instructions.
Alternatively, antibodies of the invention can be synthesized by recombinant DNA techniques
well-known in the art. For example, antibodies can be obtained as DNA expression products
after incorporation of DNA sequences encoding the antibodies into expression vectors and
introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the
desired antibodies, from which they can be later isolated using well-known techniques.
Accordingly, a further object of the invention relates to a nucleic acid sequence
encoding an antibody according to the invention. More particularly the nucleic acid sequence
encodes an heavy chain or a light chain of an antibody of the invention.
Typically, said nucleic acid is a DNA or RNA molecule, which may be included in
any suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage or a
viral vector.
The terms "vector", "cloning vector" and "expression vector" mean the vehicle by
which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a host cell, so as
to transform the host and promote expression (e.g. transcription and translation) of the
introduced sequence.
So, a further object of the invention relates to a vector comprising a nucleic acid of the
invention.
Such vectors may comprise regulatory elements, such as a promoter, enhancer,
terminator and the like, to cause or direct expression of said antibody upon administration to a
subject. Examples of promoters and enhancers used in the expression vector for animal cell
include early promoter and enhancer of SV40 (Mizukami T. et al. 1987), LTR promoter and
enhancer of Maloney mouse leukemia virus (Kuwana Y et al. 1987), promoter (Mason JO et
al. 1985) and enhancer (Gillies SD et al. 1983) of inimunoglobulin H chain and the like.
Any expression vector for animal cell can be used, so long as a gene encoding the
human antibody C region can be inserted and expressed. Examples of suitable vectors include
pAGE 107 (Miyaji H et al. 1990), pAGE 103 (Mizukami T et al. 1987), pHSG274 (Brady G et
al. 1984), pKCR (O’Hare K et al. 1981), pSG1 beta d2(Miyaji H et al. 1990) and the like.
Other examples of plasmids include replicating plasmids comprising an origin of
replication, or integrative plasmids, such as for instance pUC, pcDNA, pBR, and the like.
Other examples of viral vector include adenoviral, retroviral, herpes virus and AAV
vectors. Such recombinant viruses may be produced by techniques known in the art, such as
by transfecting packaging cells or by transient transfection with helper plasmids or viruses.
Typical examples of virus packaging cells include PA3 17 cells, PsiCRIP cells, GPenv+ cells,
293 cells, etc. Detailed protocols for producing such replication-defective recombinant viruses
WO 96/22378, US 5,882,877, US 6,013,516, US
may be found for instance in WO 95/14785,
4,861,719, US 5,278,056 and WO 94/19478.
A further object of the present invention relates to a host cell which has been
transfected, infected or transformed by a nucleic acid and/or a vector according to the
invention.
The term ’transformation" means the introduction of a "foreign" (i.e. extrinsic or
extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the
introduced gene or sequence to produce a desired substance, typically a protein or enzyme
coded by the introduced gene or sequence. A host cell that receives and expresses introduced
DNA or RNA bas been "transformed".
The nucleic acids of the invention may be used to produce an antibody of the
invention in a suitable expression system. The term "expression system" means a host cell and
compatible vector under suitable conditions, e.g. for the expression of a protein coded for by
foreign DNA carried by the vector and introduced to the host cell.
Common expression systems include E. coli host cells and plasmid vectors, insect host
cells and Baculovirus vectors, and mammalian host cells and vectors. Other examples of host
cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells
(such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include
E.coli, Kluyveromyces or Saccharomyces yeasts, mammalian cell lines (e.g., Vero cells, CHO
cells, 3T3 cells, COS cells, etc.) as well as primary or established mammalian cell cultures
(e.g., produced from lymphoblasts, fibroblasts, embryonic cells, epithelial cells, nervous cells,
adipocytes, etc.). Examples also include mouse SP2/0-Ag14 cell (ATCC CRL1581), mouse
P3X63-Ag8.653 cell (ATCC CRL1580), CHO cell in which a dihydrofolate reductase gene
(hereinafter referred to as "DHFR gene") is defective (Urlaub G et al; 1980), rat
YB2/3HL.P2.G 11.16Ag.20 cell (ATCC CRL1662, hereinafter referred to as "YB2/0 cell"),
and the like.
The present invention also relates to a method of producing a recombinant host cell
expressing an antibody according to the invention, said method comprising the steps of: (i)
introducing in vitro or ex vivo a recombinant nucleic acid or a vector as described above into
a competent host cell, (ii) culturing in vitro or ex vivo the recombinant host cell obtained and
(iii), optionally, selecting the cells which express and/or secrete said antibody. Such
recombinant host cells can be used for the production of antibodies of the invention.
In another particular embodiment, the method comprises the steps of:
(i) culturing the hybridoma 3E3E8 under conditions suitable to allow expression of
3E3E8 antibody; and
(ii)
recovering the expressed antibody.
Antibodies of the invention are suitably separated from the culture medium by
conventional immunoglobulin purification procedures such as, for example, protein A-
Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity
chromatography.
In a particular embodiment, the human chimeric antibody of the present invention can
be produced by obtaining nucleic sequences encoding VL and VH domains as previously
described, constructing a human chimeric antibody expression vector by inserting them into
an expression vector for animal cell having genes encoding human antibody CH and human
antibody CL, and expressing the coding sequence by introducing the expression vector into an
animal cell.
As the CH domain of a human chimeric antibody, it may be any region which belongs
to human immunoglobulin, but those of IgG class are suitable and any one of subclasses
belonging to IgG class, such as IgGi, IgG2, IgG3 and IgG4, can also be used. Also, as the CL
of a human chimeric antibody, it may be any region which belongs to Ig, and those of kappa
class or lambda class can be used.
Methods for producing chimeric antibodies involve conventional recombinant DNA
and gene transfection techniques are well known in the art (See Morrison SL. et al. (1984) and
patent documents US5,202,238; and US5,204, 244).
The humanized antibody of the present invention may be produced by obtaining
nucleic acid sequences encoding CDR domains, as previously described, constructing a
humanized antibody expression vector by inserting them into an expression vector for animal
cell having genes encoding (i) a heavy chain constant region identical to that of a human
antibody and (ii) a light chain constant region identical to that of a human antibody, and
expressing the genes by introducing the expression vector into an animal cell.
The humanized antibody expression vector may be either of a type in which a gene
encoding an antibody heavy chain and a gene encoding an antibody light chain exists on
separate vectors or of a type in which both genes exist on the same vector (tandem type). In
respect of easiness of construction of a humanized antibody expression vector, easiness of
introduction into animal cells, and balance between the expression levels of antibody H and L
chains in animal cells, humanized antibody expression vector of the tandem type is preferred
_10 -
(Shitara K et al. 1994). Examples of tandem type humanized antibody expression vector
include pKAINTEX93 (WO 97/10354), pEE 18 and the like.
Methods for producing humanized antibodies based on conventional recombinant
DNA and gene transfection techniques are well known in the art (See, e. g., Riechmann L. et
al. 1988; Neuberger MS. et at. 1985). Antibodies can be humanized using a variety of
techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT
publication W091/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or
resurfacing (EP 592,106; EP 519,596; Padlan EA (1991); Studnicka GM et al. (1994);
Roguska MA. et at. (1994)), and chain shuffling (U.S. Pat. No.5,565,332). The general
recombinant DNA technology for preparation of such antibodies is also known (see European
Patent Application EP 125023 and International Patent Application WO 96/02576).
The Fab of the present invention can be obtained by treating an antibody which
specifically reacts with AxI with a protease, papaine. Also, the Fab can be produced by
inserting DNA encoding Fab of the antibody into a vector for prokaryotic expression system,
or for eukaryotic expression system, and introducing the vector into a procaryote or eucaryote
(as appropriate) to express the Fab.
The F(ab’)2 of the present invention can be obtained treating an antibody which
specifically reacts with Axl with a protease, pepsin. Also, the F(ab’)2 can be produced by
binding Fab described below via a thioether bond or a disulfide bond.
The Fab’ of the present invention can be obtained treating F(ab’)2 which specifically
reacts with Axi with a reducing agent, dithiothreitol. Also, the Fab’ can be produced by
inserting DNA encoding Fab fragment of the antibody into an expression vector for
prokaryote, or an expression vector for eukaryote, and introducing the vector into a
prokaryote or eukaryote (as appropriate) to perform its expression.
The scFv of the present invention can be produced by obtaining cDNA encoding the
VH and VL domains as previously described, constructing DNA encoding scFv, inserting the
DNA into an expression vector for prokaryote, or an expression vector for eukaryote, and then
introducing the expression vector into a prokaryote or eukaryote (as appropriate) to express
the scFv. To generate a humanized scFv fragment, a well known technology called CDR
grafting may be used, which involves selecting the complementary determining regions
(CDRs) from a donor scFv fragment, and grafting them onto a human scFv fragment
framework of known three dimensional structure (see, e. g., W098/45322; WO 87/02671;
US5,859,205; US5,585,089; US4,8 16,567; EPO 173494).
Amino acid sequence modification(s) of the antibodies described herein are
contemplated. For example, it may be desirable to improve the binding affinity and/or other
biological properties of the antibody. It is known that when a humanized antibody is produced
by simply grafting only CDRs in VH and VL of an antibody derived from a non-human
animal in FRs of the VH and VL of a human antibody, the antigen binding activity is reduced
in comparison with that of the original antibody derived from a non-human animal. It is
considered that several amino acid residues of the VH and VL of the non-human antibody, not
only in CDRs but also in FRs, are directly or indirectly associated with the antigen binding
activity. Hence, substitution of these amino acid residues with different amino acid residues
derived from FRs of the VH and VL of the human antibody would reduce of the binding
activity. In order to resolve the problem, in antibodies grafted with human CDR, attempts
have to be made to identify, among amino acid sequences of the FR of the VH and VL of
human antibodies, an amino acid residue which is directly associated with binding to the
antibody, or which interacts with an amino acid residue of CDR, or which maintains the
three-dimensional structure of the antibody and which is directly associated with binding to
the antigen. The reduced antigen binding activity could be increased by replacing the
identified amino acids with amino acid residues of the original antibody derived from a non-
human animal.
Modifications and changes may be made in the structure of the antibodies of the
present invention, and in the DNA sequences encoding them, and still obtain a functional
molecule that encodes an antibody with desirable characteristics.
In making the changes in the amino sequences, the hydropathic index of amino acids
may be considered. The importance of the hydropathic amino acid index in conferring
interactive biologic function on a protein is generally understood in the art. It is accepted that
the relative hydropathic character of the amino acid contributes to the secondary structure of
the resultant protein, which in turn defines the interaction of the protein with other molecules,
for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each
amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and
charge characteristics these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8)
phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-
0.4); threonine (47); serine (48); tryptophane (49); tyrosine (-1.3); proline (-1.6); histidine
lysine (-3.9); and
(-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5);
arginine (4.5).
A further object of the present invention also encompasses function-conservative
variants of the antibodies of the present invention.
"Function-conservative variants" are those in which a given amino acid residue in a
protein or enzyme has been changed without altering the overall conformation and function of
the polypeptide, including, but not limited to, replacement of an amino acid with one having
similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic,
hydrophobic, aromatic, and the like). Amino acids other than those indicated as conserved
may differ in a protein so that the percent protein or amino acid sequence similarity between
any two proteins of similar function may vary and may be, for example, from 70 % to 99 % as
determined according to an alignment scheme such as by the Cluster Method, wherein
similarity is based on the MEGALIGN algorithm. A "function-conservative variant" also
includes a polypeptide which has at least 60 % amino acid identity as determined by BLAST
or PASTA algorithms, preferably at least 75 more preferably at least 85%, still preferably
at least 90 %, and even more preferably at least and which has the same or substantially
95%,
similar properties or functions as the native or parent protein to which it is compared.
Two amino acid sequences are "substantially homologous" or "substantially similar"
when greater than 80 %, preferably greater than 85 %, preferably greater than 90 % of the
amino acids are identical, or greater than about 90 %, preferably greater than 95 %, are similar
(functionally identical) over the whole length of the shorter sequence. Preferably, the similar
or homologous sequences are identified by alignment using, for example, the GCG (Genetics
Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin)
pileup program, or any of sequence comparison algorithms such as BLAST, FASTA, etc.
For example, certain amino acids may be substituted by other amino acids in a protein
structure without appreciable loss of activity. Since the interactive capacity and nature of a
protein define the protein’s biological functional activity, certain amino acid substitutions can
be made in a protein sequence, and, of course, in its DNA encoding sequence, while
nevertheless obtaining a protein with like properties. it is thus contemplated that various
changes may be made in the antibodies sequences of the invention, or corresponding DNA
sequences which encode said antibodies, without appreciable loss of their biological activity.
it is known in the art that certain amino acids may be substituted by other amino acids
having a similar hydropathic index or score and still result in a protein with similar biological
activity, i.e. still obtain a biological functionally equivalent protein.
As outlined above, amino acid substitutions are generally therefore based on the
relative similarity of the amino acid side-chain substituents, for example, their
hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take
various of the foregoing characteristics into consideration are well known to those of skill in
the art and include: arginine and lysine; glutamate and aspartate; serine and threonine;
glutamine and asparagine; and valine, leucine and isoleucine.
Accordingly, the invention also provides an antibody comprising a heavy chain
wherein the variable domain comprises:
- a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID
NO: 2,
- a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID
110
NO: 3,
- a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID
NO: 4,
- a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID
NO: 6,
identity with sequence set forth as SEQ ID
- a L-CDR2 having at least 90% or 95%
NO: 7,
identity with sequence set forth as SEQ ID
- a L-CDR3 having at least 90% or 95%
NO: 8, and
-that specifically binds to Axl with substantially the same affinity as an antibody
comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-
CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein
SEQ ID NO: 7 for L-CDR2 and
the variable domain comprises SEQ ID NO: 6 for L-CDR1,
8 for L-CDR3, and more preferably with substantially the same affinity as the
SEQ ID NO:
murine anti-Ax! antibody 3E3E8.
Accordingly, the invention also provides an antibody which binds to FN3 domain 1
and FN3 domain 2 of the extracellular part of AxI (epitope amino acid sequences of Axl SEQ
ID NO:9 and SEQ ID: 10).
Said antibodies may be assayed for specific binding by any method known in the art.
Many different competitive binding assay format(s) can be used for epitope binning. The
immunoassays which can be used include, but are not limited to, competitive assay systems
using techniques such western blots, radio immuno assays, ELISA, "sandwich" immunoassays,
immunoprecipitation assays, precipitin assays, gel diffusion precipitin assays,
immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, and
complement-fixation assays. Such assays are routine and well known in the art (see, e.g.,
Ausubel et al., eds, 1994 Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons,
Inc., New York). For example, the BIACOREfi (GE Healthcare, Piscaataway, NJ) is one of a
variety of surface plasmon resonance assay formats that are routinely used to epitope bin
panels of monoclonal antibodies. Additionally, routine cross-blocking assays such as those
described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow
and David Lane, 1988, can be performed.
Engineered antibodies of the invention include those in which modifications have been
made to framework residues within VH and/or VL, e.g. to improve the properties of the
antibody. Typically such framework modifications are made to decrease the immunogenicity
of the antibody. For example, one approach is to "backmutate" one or more framework
residues to the corresponding germline sequence. More specifically, an antibody that has
undergone somatic mutation may contain framework residues that differ from the germline
sequence from which the antibody is derived. Such residues can be identified by comparing
the antibody framework sequences to the germline sequences from which the antibody is
derived. To return the framework region sequences to their germline configuration, the
somatic mutations can be "backmutated" to the germline sequence by, for example, site-
directed mutagenesis or PCR-mediated mutagenesis. Such "backmutated" antibodies are also
intended to be encompassed by the invention. Another type of framework modification
involves mutating one or more residues within the framework region, or even within one or
more CDR regions, to remove T cell -epitopes to thereby reduce the potential immunogenicity
of the antibody. This approach is also referred to as "deimmunization" and is described in
further detail in U.S. Patent Publication No. 20030153043 by Carr et al.
In addition or alternative to modifications made within the framework or CDR
regions, antibodies of the invention may be engineered to include modifications within the Fe
region, typically to alter one or more functional properties of the antibody, such as serum
half-life, complement fixation, Fe receptor binding, and/or antigen-dependent cellular
cytotoxicity. Furthermore, an antibody of the invention may be chemically modified (e.g., one
or more chemical moieties can be attached to the antibody) or be modified to alter its
glycosylation, again to alter one or more functional properties of the antibody. Each of these
embodiments is described in further detail below. The numbering of residues in the Fe region
is that of the EU index of Kabat.
In one embodiment, the hinge region of CH1 is modified such that the number of
cysteine residues in the hinge region is altered, e.g., increased or decreased. This approach is
by Bodmer etal. The number of cysteine
described further in U.S. Patent No. 5,677,425
residues in the hinge region of CH 1 is altered to, for example, facilitate assembly of the light
and heavy chains or to increase or decrease the stability of the antibody.
In another embodiment, the Fe hinge region of an antibody is mutated to decrease the
biological half-life of the antibody. More specifically, one or more amino acid mutations are
introduced into the CH2-CH3 domain interface region of the Fe-hinge fragment such that the
antibody has impaired Staphylococcyl protein A (SpA) binding relative to native Fe-hinge
6,165,745
domain SpA binding. This approach is described in further detail in U.S. Patent No.
by Ward et al.
In another embodiment, the antibody is modified to increase its biological half-life.
Various approaches are possible. For example, one or more of the following mutations can be
introduced: T252L, T2545, T256F, as described in U.S. Patent No. 6,277,375 by Ward.
Alternatively, to increase the biological half life, the antibody can be altered within the CHI
or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2
domain of an Fe region of an IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121 ,022
by Presta et al.
In yet other embodiments, the Fe region is altered by replacing at least one amino acid
residue with a different amino acid residue to alter the effector functions of the antibody. For
example, one or more amino acids can be replaced with a different amino acid residue such
that the antibody has an altered affinity for an effector ligand but retains the antigen-binding
ability of the parent antibody. The effector ligand to which affinity is altered can be, for
example, an Fe receptor or the C component of complement. This approach is described in
further detail in U.S. Patent Nos. 5,624,821 and 5,648,260, both by Winter et al.
In another embodiment, one or more amino acids selected from amino acid residues
can be replaced with a different amino acid residue such that the antibody has altered Cl q
binding and/or reduced or abolished complement dependent eytotoxicity (CDC). This
approach is described in further detail in U.S. Patent Nos. 6,194,551 by Idusogie et al.
In another embodiment, one or more amino acid residues are altered to thereby alter
the ability of the antibody to fix complement. This approach is described further in PCT
Publication WO 94/29351 by Bodmer et al.
In yet another embodiment, the Fc region is modified to increase the ability of the
antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the
affinity of the antibody for an Fe receptor by modifying one or more amino acids. This
approach is described further in PCT Publication WO 00/42072 by Presta. Moreover, the
binding sites on human IgGI for FcyRI, FcyRII, FcyRIII and FeRn have been mapped and
variants with improved binding have been described (see Shields, R. L. et at., 2001 J. Biol.
Chen. 276:6591-6604, W02010106180).
In still another embodiment, the glycosylation of an antibody is modified. For
example, an aglycoslated antibody can be made (i.e., the antibody lacks glycosylation).
Glycosylation can be altered to, for example, increase the affinity of the antibody for the
antigen. Such carbohydrate modifications can be accomplished by, for example, altering one
or more sites of glycosylation within the antibody sequence. For example, one or more amino
acid substitutions can be made that result in elimination of one or more variable region
framework glycosylation sites to thereby eliminate glycosylation at that site. Such
aglycosylation may increase the affinity of the antibody for antigen. Such an approach is
described in further detail in U.S. Patent Nos. 5,714,350 and 6,350,861 by Co et al.
Additionally or alternatively, an antibody can be made that has an altered type of
glycosylation, such as a hypofucosylated or non-fucosylated antibody having reduced
amounts of or no fucosyl residues or an antibody having increased bisecting GlcNac
structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC
ability of antibodies. Such carbohydrate modifications can be accomplished by, for example,
expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered
glycosylation machinery have been described in the art and can be used as host cells in which
to express recombinant antibodies of the invention to thereby produce an antibody with
altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a
functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies
expressed in such a cell line exhibit hypofiacosylation or are devoid of fucosyl residues.
Therefore, in one embodiment, the antibodies of the invention may be produced by
recombinant expression in a cell line which exhibit hypofucosylation or non-fucosylation
pattern, for example, a mammalian cell line with deficient expression of the FUT8 gene
encoding fucosyltransferase. PCT Publication WO 03/035835 by Presta describes a variant
CHO cell line, Lecl3 cells, with reduced ability to attach fucose to Asn(297)-linked
carbohydrates, also resulting in hypoflicosylation of antibodies expressed in that host cell (see
also Shields, R.L. et al., 2002 J. Biol. Chem. 277:26733-26740). PCT Publication WO
99/54342 by Umana et al. describes cell lines engineered to express glycoprotein-modifying
glycosyl transferases (e.g., beta(1,4)-N acetylgiucosaminyltransferase III (GnTIII)) such that
antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures
which results in increased ADCC activity of the antibodies (see also Umana et al., 1999 Nat.
Biotech. 17:176-180). Eureka Therapeutics further describes genetically engineered CHO
mammalian cells capable of producing antibodies with altered mammalian glycosylation
pattern devoid of fucosyl residues
(http://www.eurekainc.com/a&boutus/companyoverview.html) . Alternatively, the antibodies
of the invention can be produced in yeasts or filamentous fungi engineered for mammalian-
like glycosylation pattern and capable of producing antibodies lacking fucose as glycosylation
pattern (see for example EP1297172131).
Another modification of the antibodies herein that is contemplated by the invention is
pegylation. An antibody can be pegylated to, for example, increase the biological (e.g.,
serum) half-life of the antibody. To pegylate an antibody, the antibody, or fragment thereof;
typically is reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde
derivative of PEG, under conditions in which one or more PEG groups become attached to the
antibody or antibody fragment. The pegylation can be carried out by an acylation reaction or
an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble
polymer). As used herein, the term "polyethylene glycol" is intended to encompass any of the
forms of PEG that have been used to derivatize other proteins, such as mono (Cl- CIO)
alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In certain
embodiments, the antibody to be pegylated is an aglycosylated antibody. Methods for
pegylating proteins are known in the art and can be applied to the antibodies of the invention.
See for example, EP 0 154 316 by Nishimura et al. and EP 0 401384 bylshikawa et al.
Another modification of the antibodies that is contemplated by the invention is a
conjugate or a protein fusion of at least the antigen-binding region of the antibody of the
invention to serum protein, such as human serum albumin or a fragment thereof to increase
half-life of the resulting molecule. Such approach is for example described in Ballance et al.
EP0322094.
Another possibility is a fusion of at least the antigen-binding region of the antibody of
the invention to proteins capable of binding to serum proteins, such human serum albumin to
increase half life of the resulting molecule. Such approach is for example described in Nygren
et al., EP 0 486 525.
Immunoconjuates:
An antibody of the invention can be conjugated with a detectable label to form an anti-
Axi immuno conjugate. Suitable detectable labels include, for example, a radioisotope, a
fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label or
colloidal gold. Methods of making and detecting such detectably-labeled immunoconjugates
are well-known to those of ordinary skill in the art, and are described in more detail below.
The detectable label can be a radioisotope that is detected by autoradiography.
125j 1311
Isotopes that are particularly useful for the purpose of the present invention are 3H,
14C.
Anti-Axl immunoconjugates can also be labeled with a fluorescent compound. The
presence of a fluorescently-labeled antibody is determined by exposing the immunoconjugate
to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent
labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin,
phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
Alternatively, anti-Axl immunoconjugates can be detectably labeled by coupling an
antibody to a chemiluminescent compound. The presence of the chemiluminescent-tagged
immunoconjugate is determined by detecting the presence of luminescence that arises during
the course of a chemical reaction. Examples of chemiluminescent labeling compounds include
luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an
oxalate ester.
Similarly, a bioluminescent compound can be used to label anti-AxI
immunoconjugates of the present invention. Bioluminescence is a type of chemiluminescence
found in biological systems in which a catalytic protein increases the efficiency of the
chemiluminescent reaction. The presence of a bioluminescent protein is determined by
detecting the presence of luminescence. Bioluminescent compounds that are useful for
labeling include luciferin, luciferase and aequorin.
Alternatively, anti-Axi immuno conjugates can be detectably labeled by linking an
anti-Axl monoclonal antibody to an enzyme. When the anti-Axl-enzyme conjugate is
incubated in the presence of the appropriate substrate, the enzyme moiety reacts with the
substrate to produce a chemical moiety which can be detected, for example, by
spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to
detectably label polyspecific immunoconjugates include 3-galactosidase, glucose oxidase,
peroxidase and alkaline phosphatase.
Those of skill in the art will know of other suitable labels which can be employed in
accordance with the present invention. The binding of marker moieties to anti-Axl
monoclonal antibodies can be accomplished using standard techniques known to the art.
Typical methodology in this regard is described by Kennedy etal., Gun. Chim. Acta 70:1,
1976; Schurs etal., Clin. Chim. Acta 81:1, 1977; Shih etal., Int’!J. Cancer 46:1101, 1990;
Stein etal., Cancer Res. 50: 1330, 1990; and Coligan, supra.
Moreover, the convenience and versatility of immunochemical detection can be
enhanced by using anti-Axi monoclonal antibodies that have been conjugated with avidin,
streptavidin, and biotin. Wilchek (eds.), "Avidin-Biotin Technology,"
(See, e.g., et al.
Methods In Enzyrno!ogy (Vol. 184) (Academic Press 1990); Bayer et al., "Immunochemical
149-
Applications of Avidin-Biotin Technology," in Methods In Molecular Biology (Vol. 10)
162 (Manson, ed., The Humana Press, Inc. 1992).)
(See, e.g., Cook and Self,
Methods for performing immunoassays are well-established.
Monoclonal Antibodies.
"Monoclonal Antibodies in Diagnostic Immunoassays," in
Production, Engineering, and Clinical Application 180-208 (Ritter and Ladyman, eds.,
Cambridge University Press 1995); Perry, "The Role of Monoclonal Antibodies in the
Advancement of Immunoassay Technology," in Monoclonal Antibodies: Principles and
Applications 107-120 (Birch and Lennox, eds., Wiley-Liss, Inc. 1995); Diamandis,
Immunoassay (Academic Press, Inc. 1996).)
In another aspect, the present invention provides an anti-AxI monoclonal antibody-
drug conjugate. An "anti-Axi monoclonal antibody-drug conjugate" as used herein refers to
an anti-AxI monoclonal antibody according to the invention conjugated to a therapeutic agent.
Such anti-Axl monoclonal antibody-drug conjugates produce clinically beneficial effects on
Axl-expressing cells when administered to a subject, such as, for example, a subject with a
Axi-expressing cancer, typically when administered alone but also in combination with other
therapeutic agents.
In typical embodiments, an anti-AxI monoclonal antibody is conjugated to a cytotoxic
agent, such that the resulting antibody-drug conjugate exerts a cytotoxic or cytostatic effect on
a Axi-expressing cancer cell) when taken up or internalized by the
a Axl-expressing cell (e.g.,
cell. Particularly suitable moieties for conjugation to antibodies are chemotherapeutic agents,
prodrug converting enzymes, radioactive isotopes or compounds, or toxins. For example, an
anti-AxI monoclonal antibody can be conjugated to a cytotoxic agent such as a
a cytostatic or cytocidal agent such as, for example,
chemotherapeutic agent or a toxin (e.g.,
abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin).
Useful classes of cytotoxic agents include, for example, antitubulin agents, auristatins,
platinum
DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g.,
complexes such as cis-platin, mono(platinum), bis(platinum) and tn-nuclear platinum
complexes and-carboplatin), anthracyclines, antibiotics, antifo lates, antimetabo lites,
chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores,
lexitropsins, nitrosoureas, platino ls, pre-forming compounds, purine antimetabo lites,
puromycins, radiation sensitizers, steroids, taxanes, topoisomerase inhibitors, ymca alkaloids,
or the like.
Individual cytotoxic agents include, for example, an androgen, anthramycin (AMC),
asparaginase, 5 -azacytidine, azathioprine, bleomycin, busulfan, buthionine sulfoximine,
42:999-1004,
camptothecin, carboplatin, carmustine (BSNU), CC-1065 (Li et al., Cancer Res.
1982), chiorambucil, cisplatin, coichicine, cyclophosphamide, cytarabine, cytidine
arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin),
daunorubicin, decarbazine, docetaxel, doxorubicin, an estrogen, 5-fluordeoxyuridine, etopside
phosphate (VP-16), 5-fluorouracil, gramicidin D, hydroxyurea, idarubicin, ifosfamide,
irinotecan, lomustine (CCNU), mechlorethamine, melphalan, 6-mercaptopurine,
methotrexate, mithramycin, mitomycin C, mitoxantrone, nitroimidazo le, paclitaxel,
plicamycin, procarbizine, streptozotocin, tenoposide (VM-26), 6-thioguanine, thioTEPA,
topotecan, vinblastine, vincristine, and vinorelbine.
(e.g., auristatin
Particularly suitable cytotoxic agents include, for example, dolastatins
(e.g., enediynes and lexitropsins),
E, AFP, MMAF, MMAE), DNA minor groove binders
paclitaxel and docetaxel), puromycins, ymca alkaloids, CC-
duocarmycins, taxanes (e.g.,
1065, SN-3 8 (7-ethyl-1 0-hydroxy-camptothein), topotecan, morpho lino-doxorubicin,
rhizoxin, cyanomorpho lino-doxorubicin, echinomycin, combretastatin, netropsin, epothilone
A and B, estramustine, cryptophysins, cemadotin, maytansinoids, discodermolide,
eleutherobin, and rnitoxantrone.
In certain embodiments, a cytotoxic agent is a conventional chemotherapeutic such as,
for example, doxorubicin, paclitaxel, melphalan, ymca alkaloids, methotrexate, mitomycin C
or etoposide. In addition, potent agents such as CC-1065 analogues, calicheamicin,
maytansine, analogues of dolastatin 10, rhizoxin, and palytoxin can be linked to an anti-Axl-
expressing antibody.
In specific variations, the cytotoxic or cytostatic agent is auristatin E (also known in
e.g.,
the art as dolastatin-10) or a derivative thereof Typically, the auristatin E derivative is,
an ester formed between auristatin E and a keto acid. For example, auristatin E can be reacted
with paraacetyl benzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively.
Other typical auristatin derivatives include AFP (dimethylvaline-valine-dolaisoleuine-
dolaproine-phenylalanine-p-phenylenediamine), MMAF (dovaline-valine-dolaisoleunine-
dolaproine-phenylalanine), and MAE (monomethyl auristatin E). The synthesis and structure
of auristatin E and its derivatives are described in U.S. Patent Application Publication No.
and ;
20030083263; International Patent Publication Nos.
,780,588; 5,665,860;
and U.S. Patent Nos. 6,884,869; 6,323,315; 6,239,104; 6,034,065;
,521,284; 5,504,191; 5,410,024;
,663,149; 5,635,483; 5,599,902; 5,554,725; 5,530,097;
4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,414.
,138,036; 5,076,973;
(See,
In other variations, the cytotoxic agent is a DNA minor groove binding agent.
e.g., U.S. Patent No. 6,130,237.) For example, in certain embodiments, the minor groove
binding agent is a CBI compound. In other embodiments, the minor groove binding agent is
an enediyne (e.g., calicheamicin).
In certain embodiments, an antibody-drug conjugate comprises an anti-tubulin agent.
Taxolfi (paclitaxel),
Examples of anti-tubulin agents include, for example, taxanes (e.g.,
vincristine, vinblastine,
Taxoterefi (docetaxel)), T67 (Tularik), ymca alkyloids (e.g.,
auristatin E, AFP, MMAF, MMAE, AEB,
vindesine, and vinorelbine), and dolastatins (e.g.,
AEVB). Other antitubulin agents include, for example, baccatin derivatives, taxane analogs
epothilone A and B), nocodazole, colehicine and colcimid, estramustine, cryptophysins,
(e.g.,
cemadotin, maytansinoids, combretastatins, discodermolide, and eleutherobin. In some
embodiments, the cytotoxic agent is a maytansinoid, another group of anti-tubulin agents. For
example, in specific embodiments, the maytansinoid is maytansine or DM-1 (ImmunoGen,
52:127-131, 1992).
Inc.; see also Chari et al., Cancer Res.
In other embodiments, the cytotoxic agent is an antimetabolite. The antimetabolite can
azothioprine or mycophenolate mofetil), a
be, for example, a purine antagonist (e.g.,
dihydrofo late reductase inhibitor (e.g., methotrexate), acyclovir, gangcyclovir, zidovudine,
vidarabine, ribavarin, azidothyrnidine, cytidine arabinoside, amantadine, dideoxyuridine,
iododeoxyuridine, poscarnet, or trifluridine.
In other embodiments, an anti-Axl monoclonal antibody is conjugated to a pro-drug
converting enzyme. The pro-drug converting enzyme can be recombinantly fused to the
antibody or chemically conjugated thereto using known methods. Exemplary pro-drug
converting enzymes are carboxypeptidase G2, 0-glucuronidase, penicillin-V-amidase,
penicillin-G-amidase, 0-lactamase, 0-glucosidase, nitroreductase and carboxypeptidase A.
Techniques for conjugating therapeutic agents to proteins, and in particular to
antibodies, are well-known. (See, e.g., Arnon et al., "Monoclonal Antibodies For
Immunotargeting Of Drugs In Cancer Therapy," in Monoclonal Antibodies And Cancer
Therapy "Antibodies For Drug
(Reisfeld et al. eds., Alan R. Liss, Inc., 1985); Helistrom et al.,
Delivery," in Controlled Drug Delivery eds., Marcel Deiker, Inc., 2nd ed.
(Robinson et al.
1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in
Monoclonal Antibodies ’84: Biological And Clinical Applications (Pinchera et al. eds., 1985);
"Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody
In Cancer Therapy," in Monoclonal Antibodies For Cancer Detection And Therapy (Baldwin
62:119-58. See
et al. eds., Academic Press, 1985); and Thorpe et al., 1982, Immunol. Rev.
also, e.g., PCT publication WO 89/12624.)
Dia2nostic uses:
A further object of the invention relates to an anti-Axl antibody of the invention for
diagnosing and/or monitoring a cancer disease and other diseases in which Axi levels are
modified (increase or decrease).
In a preferred embodiment, antibodies of the invention may be labelled with a
detectable molecule or substance, such as a fluorescent molecule, a radioactive molecule or
any others labels known in the art as above described. For example, an antibody of the
invention may be labelled with a radioactive molecule by any method known to the art. For
example radioactive molecules include but are not limited radioactive atom for scintigraphic
studies such as 1123, 1124, Ini 11, Re 186, Re 188. Antibodies of the invention may be also
labelled with a spin label for nuclear magnetic resonance (NMR) imaging (also known as
magnetic resonance imaging, mn), such as iodine-123, iodine-131, indium-Ill, fluorine-19,
carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Following administration
of the antibody, the distribution of the antibody within the patient is detected. Methods for
detecting distribution of any specific label are known to those skilled in the art and any
appropriate method can be used. Some non-limiting examples include, computed tomography
(CT), position emission tomography (PET), magnetic resonance imaging (Mifi),
fluorescence, chemiluminescence and sonography.
Antibodies of the invention may be useful for diagnosing and staging of cancer
diseases associated with Axi overexpression (e.g., in radioimaging). Cancer diseases
associated with Axl overexpression typically include but are not limited to squamous cell
cancer, small-cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer,
glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer,
liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal
cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer,
prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, sarcomas, hematological
cancers (leukemias), astrocytomas, and various types of head and neck cancer or other Axi
expressing or overexpressing hyperproliferative diseases.
Antibodies of the invention may be useful for diagnosing diseases other than cancers
for which Axl expression is increased or decreased (soluble or cellular AxI form).
Typically, said diagnostic methods involve use of biological sample obtained from the
patient. As used herein the term "biological sample" encompasses a variety of sample types
obtained from a subject and can be used in a diagnostic or monitoring assay. Biological
samples include but are not limited to blood and other liquid samples of biological origin,
solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom
and the progeny thereof. For example, biological samples include cells obtained from a tissue
sample collected from an individual suspected of having a cancer disease associated with Axl
overexpression, and in a preferred embodiment from glioma, gastric, lung, pancreatic, breast,
prostate, renal, hepatic and endometrial. Therefore, biological samples encompass clinical
samples, cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluid, and
tissue samples.
In a particular embodiment, the invention is a method of diagnosing a cancer disease
associated with Axl overexpression in a subject by detecting Axi on cells from the subject
using the antibody of the invention. In particular, said method of diagnosing may comprise
the steps consisting of:
contacting a biological sample of a subject likely to suffer from a cancer
(a)
disease associated with Axl overexpression with an antibody according to the invention in
conditions sufficient for the antibody to form complexes with cells of the biological sample
that express Axi
(b) detecting and/or quantifying said complexes, whereby the detection of said
complexes is indicative of a cancer disease associated with Axi overexpression.
In order to monitor the cancer disease, the method of diagnosing according to the
invention may be repeated at different intervals of time, in order to determine if antibody
binding to the samples increases or decreases, whereby it is determined if the cancer disease
progresses or regresses.
In a particular embodiment, the invention is a method of diagnosing a disease
associated with the expression or the overexpression of Axi or the decrease or increase of the
soluble form of Axi, such as human immune disorders, thrombotic diseases (thrombosis and
atherothrombosis), and cardiovascular diseases can be also diagnosed by the anti-Axi
antibody of the invention.
Therapeutic uses:
Antibodies, fragments or immuno conjugates of the invention may be useful for
treating any disease associated with Axiexpression preferentially cancers. The antibodies of
the invention may be used alone or in combination with any suitable agent.
1) anti-Axi antibody of the invention may be used as treatment of hyperproliferative
diseases associated with AxI and or Gas6 expression, overexpression or activation. There are
no particular limitations on the tumor tissues, and examples include squamous cell cancer,
small-cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell
tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver
cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal cancer,
endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer, prostate
cancer, vulval cancer, thyroid cancer, hepatic carcinoma, sarcomas, hematological cancers
(leukemias), astrocytomas, and various types of head and neck cancer. More preferable
cancers are glioma, gastric, lung, pancreatic breast, prostate, renal, hepatic and endometrial. 2)
anti-Axl antibody of the invention are potential activators of the innate immune response and
may be used in the treatment of human immune disorders, such as sepsis, may be used as
adjuvants for immunization such as for vaccine and may be used as anti-infectious agents
(against bacteria, virus, parasites)3) anti-Axl antibody of the invention may protect or treat
thrombotic diseases such as venous and arterial thrombosis and atherothrombosis
anti-AxI antibody of the invention may protect, prevent or treat cardiovascular
diseases
anti-Axi antibody of the invention may prevent or inhibit the entry of viruses such
as Lassa and Ebola viruses and may be used to treat viral infections
In each of the embodiments of the treatment methods described herein, the anti-Ax 1
monoclonal antibody or anti-Axi monoclonal antibody-drug conjugate is delivered in a
manner consistent with conventional methodologies associated with management of the
disease or disorder for which treatment is sought. In accordance with the disclosure herein, an
effective amount of the antibody or antibody-drug conjugate is administered to a subject in
need of such treatment for a time and under conditions sufficient to prevent or treat the
disease or disorder.
Thus, an object of the invention relates to a method for treating a disease associated
with the expression of Axl comprising administering a subject in need thereof with a
therapeutically effective amount of an antibody, fragment or immunoconjugate of the
invention.
In the context of the invention, the term "treating" or "treatment", as used herein,
means reversing, alleviating, inhibiting the progress of, or preventing the disorder or
condition to which such term applies, or one or more symptoms of such disorder or condition.
According to the invention, the term "patient" or "patient in need thereof’ is intended
for a human affected or likely to be affected with disease associated with overexpression of
Axl.
By a "therapeutically effective amount" of the antibody of the invention is meant a
sufficient amount of the antibody to treat said cancer, at a reasonable benefit/risk ratio
applicable to any medical treatment. It will be understood, however, that the total daily usage
of the antibodies and compositions of the present invention will be decided by the attending
physician within the scope of sound medical judgment. The specific therapeutically effective
dose level for any particular patient will depend upon a variety of factors including the
disorder being treated and the severity of the disorder; activity of the specific antibody
employed; the specific composition employed, the age, body weight, general health, sex and
26 -
diet of the patient; the time of administration, route of administration, and rate of excretion of
the specific antibody employed; the duration of the treatment; drugs used in combination or
coincidental with the specific antibody employed; and like factors well known in the medical
arts. For example, it is well known within the skill of the art to start doses of the compound at
levels lower than those required to achieve the desired therapeutic effect and to gradually
increase the dosage until the desired effect is achieved.
In certain embodiments, an anti-AxI monoclonal antibody or antibody-drug conjugate
is used in combination with a second agent for treatment of a disease or disorder. When used
for treating cancer, an anti-Axl monoclonal antibody or antibody-drug conjugate of the
present invention may be used in combination with conventional cancer therapies such as,
e.g., surgery, radiotherapy, chemotherapy, or combinations thereof In certain aspects, other
therapeutic agents useful for combination cancer therapy with an anti-Axi antibody or
antibody-drug conjugate in accordance with the present invention include anti-angiogenic
agents. In some aspects, an antibody or antibody-drug conjugate in accordance with the
present invention is co-administered with a cytokine (e.g., a cytokine that stimulates an
immune response against a tumor).
In some embodiments, an anti-AxI monoclonal antibody or antibody-drug conjugate as
described herein is used in combination with a tyrosine kinase inhibitor (TKI).
In some embodiments, an anti-Axl monoclonal antibody or antibody-drug conjugate as
described herein is used in combination with another therapeutic monoclonal antibody (mAb).
Trastuzumab (Herceptin, Roche), Bevacizumab (Avastin, Roche) and Cetuximab (Erbitux,
Merck) are three such mAb that have been approved. Other mAb include, but are not limited
to: Infliximab (Remicade, Johnson&Johiison), Rituximab (Rituxan, Roche), Adalimumab
(Humira, Abbott) and Natalizumab (Tysabri, Biogen).
Pharmaceutical compositions:
For administration, the anti-Axi monoclonal antibody or antibody-drug conjugate is
formulated as a pharmaceutical composition. A pharmaceutical composition comprising an
anti-Axl monoclonal antibody or antibody-drug conjugate can be formulated according to
known methods to prepare pharmaceutically useful compositions, whereby the therapeutic
molecule is combined in a mixture with a pharmaceutically acceptable carrier. A composition
is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a
recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically
acceptable carrier. Other suitable carriers are well-known to those in the art. (See, e.g.,
Geimaro (ed.), Remington’s Pharmaceutical Sciences (Mack Publishing Company, 19th ed.
1995)) Formulations may further include one or more excipients, preservatives, solubilizers,
buffering agents, albumin to prevent protein loss on vial surfaces, etc.
The form of the pharmaceutical compositions, the route of administration, the dosage
and the regimen naturally depend upon the condition to be treated, the severity of the illness,
the age, weight, and sex of the patient, etc.
The pharmaceutical compositions of the invention can be formulated for a topical,
oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular
administration and the like.
Preferably, the pharmaceutical compositions contain vehicles which are
pharmaceutically acceptable for a formulation capable of being injected. These may be in
particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium,
potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry,
especially freeze-dried compositions which upon addition, depending on the case, of sterilized
water or physiological saline, permit the constitution of injectable solutions.
The doses used for the administration can be adapted as a function of various
parameters, and in particular as a function of the mode of administration used, of the relevant
pathology, or alternatively of the desired duration of treatment.
To prepare pharmaceutical compositions, an effective amount of the antibody may be
dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions
or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol
and sterile powders for the extemporaneous preparation of sterile injectable solutions or
dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy
syringability exists. It must be stable under the conditions of manufacture and storage and
must be preserved against the contaminating action of microorganisms, such as bacteria and
fungi.
Solutions of the active compounds as free base or pharmacologically acceptable salts
can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures
thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a
preservative to prevent the growth of microorganisms.
An antibody of the invention can be formulated into a composition in a neutral or salt
form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free
amino groups of the protein) and which are formed with inorganic acids such as, for example,
hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic,
and the like. Salts formed with the free carboxyl groups can also be derived from inorganic
bases such as, for example, sodium, potassium, ammonium calcium, or ferric hydroxides, and
such organic bases as isopropytamine, trimethylamine, histidine, procaine and the like.
The carrier can also be a solvent or dispersion medium containing, for example, water,
ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and
the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained,
for example, by the use of a coating, such as lecithin, by the maintenance of the required
particle size in the case of dispersion and by the use of surfactants. The prevention of the
action of microorganisms can be brought about by various antibacterial and antifungal agents,
for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many
cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
Prolonged absorption of the injectable compositions can be brought about by the use in the
compositions of agents delaying absorption, for example, aluminium monostearate and
gelatin.
Sterile injectable solutions are prepared by incorporating the active compounds in the
required amount in the appropriate solvent with various of the other ingredients enumerated
above, as required, followed by filtered sterilization. Generally, dispersions are prepared by
incorporating the various sterilized active ingredients into a sterile vehicle which contains the
basic dispersion medium and the required other ingredients from those enumerated above. In
the case of sterile powders for the preparation of sterile injectable solutions, the preferred
methods of preparation are vacuum-drying and freeze-drying techniques which yield a
powder of the active ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
The preparation of more, or highly concentrated solutions for direct injection is also
contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid
penetration, delivering high concentrations of the active agents to a small tumor area.
Upon formulation, solutions will be administered in a manner compatible with the
dosage formulation and in such amount as is therapeutically effective. The formulations are
easily administered in a variety of dosage forms, such as the type of injectable solutions
described above, but drug release capsules and the like can also be employed.
For parenteral administration in an aqueous solution, for example, the solution should
be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient
saline or glucose. These particular aqueous solutions are especially suitable for intravenous,
intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile
aqueous media which can be employed will be known to those of skill in the art in light of the
present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCI
solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site
of infusion, (see for example, "Remington’s Pharmaceutical Sciences" 15th Edition, pages
1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the
condition of the subject being treated. The person responsible for administration will, in any
event, determine the appropriate dose for the individual subject.
The antibodies of the invention may be formulated within a therapeutic mixture to
comprise about 0.0001 to 1.0 milligrams, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0
or even about 10 milligrams per dose or so. Multiple doses can also be administered.
In addition to the compounds formulated for parenteral administration, such as
intravenous or intramuscular injection, other pharmaceutically acceptable forms include, e.g.
tablets or other solids for oral administration; time release capsules; and any other form
currently used.
In certain embodiments, the use of liposomes and/or nanoparticles is contemplated for
the introduction of antibodies into host cells. The formation and use of liposomes and/or
nanoparticles are known to those of skill in the art.
Nanocapsules can generally entrap compounds in a stable and reproducible way. To
avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized
around 0.1 gm) are generally designed using polymers able to be degraded in vivo.
Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are
contemplated for use in the present invention, and such particles may be are easily made.
Liposomes are formed from phospholipids that are dispersed in an aqueous medium
and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar
vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 gm. Sonication of
MI-Vs results in the formation of small unilamellar vesicles (SUVs) with diameters in the
containing an aqueous solution in the core. The physical
range of 200 to 500 A,
characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations.
Kits:
Finally, the invention also provides kits comprising at least one antibody of the
invention. Kits containing antibodies of the invention find use in detecting Axl expression
(increase or decrease), or in therapeutic or diagnostic assays. Kits of the invention can contain
an antibody coupled to a solid support, e.g., a tissue culture plate or beads (e.g., sepharose
beads). Kits can be provided which contain antibodies for detection and quantification of Axl
in vitro, e.g. in an ELISA or a Western blot. Such antibody useful for detection may be
provided with a label such as a fluorescent or radiolabel.
The invention will be further illustrated by the following figures and examples.
However, these examples and figures should not be interpreted in any way as limiting the
scope of the present invention.
FIGURES LEGENDS:
Figure 1: ELISA experiments to investigate the affinity and the specificity of mouse
monoclonal antibodies against hAxi. Plates coated with human Axl-Fc (h-Axl), mouse Ax!-
Fc (m-Axl) or human Mer-Fe (h-Mer), TyroFc (h-Tyro-3) were incubated with anti-AxI
antibodies (mAbi, mAb2, mAb3, mAb4 or 3E3-E8). After washing, HRP-conjugated anti-
mouse TgG was added. 3E3-E8 doesn’t cross-react with h-Tyro-3 or h-Mer or m-Axl.
A549 were stained with
Figure 2: Flow cytometry analysis of cell surface Axi in A549.
monoclonal anti-Ax! antibodies (mAbi, mAb2, mAb3, mAb4 or 3E3-E8) and fluorescein-
conjugated anti-mouse IgG. Staining with 3E3-E8 results in a shift by one order of magnitude
and demonstrates Axl overexpression on the surface of these cells.
Affinity measurement of 3E3-E8 in the presence or not of Gas6 using BlAcore.
Figure 3:
(A) Without Gas6, the association rates (ka) and dissociation rates (kd) were calculated using a
(KD)
simple one-to-one Langmuir binding model. The equilibrium dissociation constant
of about
derived as the ka/kd ratio. 3E3-E8 binds to human Axl with high affinity, with a KD
1.6 nM. (B) 3E3-E8 doesn’t block the binding of ligand Gas6 to AxI.
Figure 4: ELISA experiments to investigate the effects of 3E3-E8 mAb on Axi receptor
BXPC3, Capan-1, PAINC1 and MTAPaCa-2 pancreatic cancer cells were
phosphorylation.
serum-starved, pre-incubated with mouse anti-AxI antibodies and treated with Gas6 ligand..
Cell lysates were transferred to PathScanfi Phospho-Axi (PanTyr) Sandwich ELISA plates
(RD Systems, Minneapolis, MN). Compared with other antibodies, 3E3-E8 was able to block
or significantly reduce Gas6-mediated Axi activation in the four cell lines as indicated by
decreased Axl phosphorylation levels in Gas6-stimulated cells.
Figure 5: Wound healing/scratch assay to investigate the effects of mouse anti-AxI
antibodies on cell migration and proliferation. After grown to confluency, A549 cells were
starved and wounded with a pipette tip. 3E3E8 mouse anti-Axi reduced the repopulation of
the cleared area more significantly than the mAb 1, even though the cells were treated with
Gas6.
Figure 6: Cell viability assay to investigate the anti-proliferative efficacy of anti-Axi
3E3-E8. Capan- 1, PANC 1 and MIAPaCa-2 pancreatic cancer cells were grown in medium
days. Cell viability was
and treated at the indicated concentrations of mAbi or 3E3-E8 for 5
measured by MTS. 3E3-E8 inhibits more the growth of all tested cell lines than mAb 1 and the
percentage of inhibition is concentration-dependent.
Figure 7: monoclonal anti-Axi 3E3-E8 antibody induces a rapid down-regulation of Axi
4g/ml of niAb
receptor and inhibits Akt pathway. Panel-cells were incubated with 100
3E3-E8 for different time. Cells were lyzed and total protein were used to detect by western-
blot. As shown in Figure 7A, mAb 3E3-E8 rapidly down-regulates the expression of Axl
receptor in Panel cells. After one hour incubation with mAb 3E3-E8, cells were incubated 30
minutes with Gas6 and the presence of Axi receptor phosphorylation on tyrosine 702 (AxI
activation) and phosphorylation of Akt on serine 473 (Akt activation) was analyzed by
western blot. As shown in Figure 713, mAb 3E3-E8 incubation leads to a decrease in the
Gas6-induced phosphorylation of Axi and Akt proteins.
Figure 8: Xenograft models to investigate the effects of mouse anti-Axi antibodies on
human triple negative breast cancer and human pancreatic cancer in nude mice. MDA-
MB-231 (triple negative breast cancer cells) or MIAPaca-2, BXPC3 (pancreatic cancer cells)
were implanted into the right flank of athymic nude mice. Animals received 300 jig/injection
of the mouse anti-Axl antibodies. During the treatment, the growth of tumors was monitored
once weekly with a calliper. 3E3-E8 reduced more the overall growth of pancreatic and triple
negative tumors in nude mice than mAbi (A, B, C) and significantly increase the overall
survival in comparison with vehicle or Gemcitabine in pancreatic BXPC3 xenografied mice
(D). On explanted MIAPaca-2 xenografls tumors which received two injections, a drastic
down-expression of Axi receptor by mAb 3E3-E8 is also observed (E)
Figure 9: Sequence of the hAxl-hFc and localization/sequence of the epitope of anti-Axi
mAb 3E3-E8
The epitope of anti-Ax! antibody 3E3-E8 was identified by limited proteolysis assays using
either Trypsine or GIuC proteases and MALDI mass spectrometry analysis. The figure shows
the composition of the antigen (hAxl-hFc) used in this experiment which is composed of
amino acids 33 to 440 of the extracellular domain of Axi fused to the Fc part of human IgGi
and histidine Tag. Each immunoglobuline like domains and fibronectine 3 domains of the Axi
protein is indicated on the sequence. niAb 3E3-E8 binds to two peptides (conformational
epitope) localized in the first and the second fibronectin domains (sequences are framed in the
sequence of the protein and detailed in the table).
Figure 10: Representation of a model of the ectodomain of human Axi and localization
of the epitope of anti-Axi mouse monoclonal antibody 3E3-E8 and Gas6 binding domain.
Figure 10A displays a cartoon-type representation of the model of the whole extracellular
domain of human Axi with all four domains labeled. In figure lOB, fragment from amino acid
305 to 315 of Gas6 was added as a light-grey 0 sheet, illustrating the Gas6 binding domain
within the Immunoglobulin-like domain 1 of Axi. Finally, figure 10C exhibits the 3E3-E8
epitope within the fibronectin type III domains 1 and 2 as grey surfaces. It confirms first that
the two parts of the epitope are localized on the outside surface of each domain. Secondly, the
figure 10C illustrates also that the interaction site of Gas6 and the epitope are situated far
from each other on the human Axi ectodomain.
EXAMPLE:
EXAMPLE 1: GENERATION OF MOUSE ANTI-AXL MONOCLONAL
ANTIBODY
Monoclonal antibodies against AxI were developed by sequential immunization of
Balb/c mice. Balb/c mice were hyperimmunized with human Axl extracellular domain
(hAxIECD) fused to human Fc domain (hAxl-hFc protein; R&D system). Balb/c mice were
subcutaneously injected with 10 jig of soluble hAxl-hFc on days 0, 14 and 28 in the presence
of adjuvant, Freund’s complete (first injection) or incomplete (second and third injections).
Spleen cells from mice were fused with mouse myeloma cells (PX63.Ag8.653; ATCC,
Rockville, MD) using a previously described protocol (Saihi et al. Biochem. J. 2004). Cells
were cultured in plates (10 5 per well) with HAT media for hybridoma selection. After 12
days, the supernatants were harvested and screened for Axi binding specificity (hAxl-hFc or
hFc alone) by direct enzyme-linked immunosorbent assay (ELISA). Eight positive clones,
showing the highest immunobinding after the second round of subcloning by limiting
dilution, were expanded for large scale production of mAb. Conditioned supernatants
in vitro
were purified by Protein G affinity chromatography.
EXAMPLE 2: MOUSE ANTI-AXL MONOCLONAL ANTIBODIES DO NOT
CROSS REACT WITH MOUSE AXL OR OTHER MEMBERS OF THE HUMAN
TAM RECEPTOR FAMILY
Example 2.1: Mouse anti-Axl monoclonal antibodies do not cross react with mouse
Axl or other members of the human TAM receptor family as determined by EL ISA
Briefly, hAxl-hFc coated plates were saturated with 1% bovine serum albumin (BSA)
PBS, 0.1% Tween 20 (PBST).
For cross reaction assay, coated plates were incubated with human Axl-Fc (h-Axl),
mouse Axl-Fc (m-Axl) or human Mer-Fc (h-Mer), TyroFc (h-Tyro-3) for 1 hour at 37C
and washed four times in PBST. Plates were incubated with anti-Axi mAbs (2 hours at 37C)
and washed four times in PBST. Plates were incubated with HRP-conjugated anti-mouse lgG
(Sigma) at a 1:2000 dilution in PBST, 1% BSA (1 hour at 37C). Finally, an ortho-
phenylenediamine solution (Sigma) was added for 30 min at room temperature in the dark and
the absorbance was measured at 450 nm.
The specificity against h-Axl, in a dose-specific manner, of the ten anti-hAx1ECD
mAbs selected was demonstrated (Figure 1).
Ax!-
Example 2.2: Mouse anti-Axl monoclonal antibody binds specifically
expressing cells as determined by FA CS
The ability of mouse anti-Axl monoclonal antibodies of the invention to specifically
recognize Axl expressing cells was determined by FACS using standard techniques. Briefly,
A549 cells (ATCC number: CCL-185) were harvested, stained with purified mouse anti-Axl
monoclonal antibodies of the invention at 4C for 1 hour, washed three times in PBS-BSA
0.1%, and then stained with fluorescein-conjugated anti-mouse IgG (1:50) (Sigma) at 4C in
the dark for 45
mm. Samples were analyzed on EPICS flow cytometer (Beckman-Coulter,
Fullerton, CA). As shown in Figure 2, mouse anti-Axi monoclonal antibodies of the invention
bound specifically Axl expressing-A549 cells.
Example 2.3: Affinity measurement of mouse anti-Axl monoclonal antibody
evaluated by BL4 Core
For binding affinity determination of anti-Axi antibodies, a surface Plasmon
Resonance measurement with a BlAcore-3000 instrument was used (BIACORE AB, Uppsala,
Sweden). Experiments were performed at the facilities from the platform of Proteomic
Imaging and Molecular Interactions (M. PugniŁre) located in the laboratory. To measure the
affinity between anti-Axi antibodies and the hAxl-hFc, mouse anti-Axl monoclonal antibodies
were captured by CM5 biosensor chips coated with hAxl-hFc (using an amine coupling kit
(BlAcore AB)). For measurement of kinetics, various concentrations of anti-Axl mAb (from 2
to 133 nM) in 10 mM HEPES, 150 mM NaCl, pH 7.4, 0.005% surfactant P20 buffer were
injected at 25C with a flow rate of 50 p.1/mm. Association rates (k a) and dissociation rates
(krj) were calculated using a simple one-to-one Langmuir binding model (BlAcore Evaluation
Software version 3.2). The equilibrium dissociation constant (KD) was calculated as the k /kd
ratio. As indicated (Figure 3A), 3E3-E8 showed a of 1.6x10 9M.
EXAMPLE 3: MOUSE ANTI-AXL MONOCLONAL ANTIBODY DOES NOT
BLOCK THE BINDING OF GAS6
nM) was injected on
For competition study, a saturating concentration of Gas6 (625
CM5 biosensor chips coated with hAxl-hFc (using an amine coupling kit (BlAcore AB)).
Mouse anti-Axl monoclonal antibody (666 nM) was injected without removing Gas6. The
same experiment was performed injecting firstly the mouse anti-Axl monoclonal antibody
(666 riM) and secondly Gas6 (625 nM). Results showed that 3E3-E8 did not compete with
Gas6 ligand for hAx1ECD (Figure 313).
EXAMPLE 4: MOUSE ANTI-AXL MONOCLONAL ANTIBODY OF THE
INVENTION INHIBITS LICAND INDUCED AXL PHOSPHORYLATION IN VITRO
ELISA experiments were performed in order to investigate whether the mouse anti-
Axi monoclonal antibody of the invention was able to block ligand Gas6-induced
-
phosphorylation of AxI. In brief; BXPC3 (ATCC number: CRL-1687), Capan-1 (ATCC
number: HTB-79), PANC1 (ATCC number: CRL-1469) and MIAPaCa-2 (ATCC number:
CRL-1420) cells were seeded in normal growth medium in flat-bottom 6 well plates. The next
day, growth medium was replaced by serum-free medium to starve cells over night for 24
hours. Cells were pre-incubated with 100 tg/mL of purified mouse monoclonal anti-Axl of
ng/mL Gas6 incubated with Gas6 for 30
the invention, and then treated with or without 250
min at 37C. Afterwards, medium was removed, cells were lysed in 50 jtL of lysis buffer (20
(vlv), 10%
ruM Tris pH 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100
7.5,
glycerol (v/v), 100 mM sodium fluoride, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM
sodium orthovanadate (Sigma)) supplemented with phosphatase and protease inhibitors
(Roche Diagnostics, Meylan, France) for 30 mm. Cell debris were removed by centrifugation
and the protein concentrations were determined by Bradford colorimetric reaction. The
PathScanfi Phospho-Axl (PanTyr) Sandwich ELISA Kit (RD Systems, Minneapolis, MN)
was used as described by the manufacturer for the detection of phospho-Axi level measuring
absorbance at 450 nm in a colorimetric assay.
As shown in Figure 4, mAb 3E3-E8 strongly inhibited Gas6 ligand-induced Axi
phosphorylation in all pancreatic cancer cell lines. Other mAbs did not or slightly inhibit
Gas6 ligand-induced Axl phosphorylation in all pancreatic cancer cell lines.
EXAMPLE 5: MOUSE MONOCLONAL ANTIBODY ANTI-AXL OF THE
INVENTION INHIBITS CELL MIGRATION
A wound healing assay was performed observing the healing process in which the
cells on the edges of the artificial wound migrate toward the wound area. A549 cells were
cultured to confluence or near confluence (>90%) in 24 well plates. A wound field was
created at the center of the well using a sterile pipette tip. Migratory cells are able to extend
protrusions and ultimately invade and close the wound field. The cells were rinsed very gently
and incubated with purified mouse anti-Axl monoclonal antibodies of the invention
with PBS
with or without 100 pg/mL of Gas6. Cell migration rate was determined 24
(100 p.gImL)
hours after treatment using microscopic imaging. As shown in Figure 5, mAb 3E3-E8
strongly inhibited cell migration as healing area was still visible in contrast to mAbi or Gas6
treated cells.
EXAMPLE 6: MOUSE MONOCLONAL ANTIBODY ANTI-AXL OF THE
INVENTION INHIBITS CELL PROLIFERATION
MIAPaca-2, Capan-1 and PANC1 pancreatic cancer cells were seeded at 4000
(25, 50 or
cells/well in 96-well plates and treated with mouse anti-Axi monoclonal antibodies
days. Cell proliferation assays were carried out using the MTS assay (3-
100 tg/mL) for 5
(4,5-dimethylthiazolyl)-5 -(3-carboxymethoxyphenyl)(4-sulfophenyl)-2H-tetrazolium).
MTS is reduced by cells into a formazan product that is soluble in tissue culture medium. The
absorbance of the formazan at 490 mn was measured using a spectrophotometer. As shown in
Figure 6, mAb 3E3-E8 strongly inhibited the proliferation of pancreatic cells while a slight
inhibition was observed with the other AxI-specific antibody (mAbi).
THE MOUSE ANTI-HUMAN AXL MONOCLONAL
EXAMPLE 7:
ANTIBODY OF THE INVENTION DOWN-REGULATES AXL EXPRESSION AND
INHIBITS AKT PATHWAY
To decipher the mechanism involved in the inhibition of cell migration and AxI
phosphorylation by mAb 3E3-E8, its direct effect on Axl receptor and downstream signaling
pathways were analyzed (activation of Axi receptor by Gas6 ligand has been reported to
induce several key signaling cascade notably the AKT pathway). The down-regulation of Axl
receptor and the phosphorylation of Axi receptor and Akt were analyzed in a pancreatic
cancer cell line (Pane-i cells) treated with 3E3-E8 mAb by western blot.
(1X106
cells per
Pancreatic cancer cell line, Pane-i cells, were plated in 6 wells plate
well) and incubated with 100 ug/mi 3E3-E8 at 37C. Cell lines harvested at different time
point were lysed with buffer (150 ruM NaCl, 10 mM TRIS pH7.4, 1mM EDTA, 1% TRITON
X100) containing 2 mM phenylmethylsulfonyl fluoride, 100 mM sodium fluorure, 10 mM
sodium orthovanadate, and one tablet of complete protease inhibitor mixture (Sigma, St
Louis, MO). After a resolving on 8%- or 10%-SDS-PAGE under reducing conditions, the
proteins were transferred onto polyvinylidene difluoride membranes (Millipore, Bedford,
nonfat dry milk.
MA) which were then saturated in PBS containing 0.1% Tween 20 and 5%
Membranes were incubated over-night at 4C with appropriate dilutions of anti-human-AXL
(R&D systems), anti-phospho (Y702) Axl or anti-phospho (S473) Akt from Cell Signaling
Technology. Immunoblots were normalized using an antibody directed to GAPDH
(Millipore). Membranes were then incubated with appropriated horseradish peroxidase-
conjugated secondary antibodies (Bio-Rad) and processed for ECL detection (Amersham) and
analysis with G:BOX iChemi (Syngene).
When cells were treated with mAb 3E3-E8, AxI expression decreases rapidly after 90
minutes and is almost undetectable after 24 hours (Figure 7A). An induction of the amount of
phospho-Axl and phospho-Akt was observed when cells were stimulated with Gas6. Both
signals were dramatically inhibited by pre-treatment with mAb 3E3-E8 (Figure 7B).
EXAMPLE 8: THE MOUSE ANTI-HUMAN AXL MONOCLONAL
ANTIBODY OF THE INVENTION REDUCES HUMAN TRIPLE NEGATIVE
IN VIVO
BREAST CANCER AND PANCREATIC CANCER GROWTH
ASSOCIATED WITH THE DOWN-REGULATION OF AXL RECEPTOR
All in vivo experiments were performed in compliance with the French guidelines for
experimental animal studies (Agreement no. C3427). Six-week old female athymic nude
106;
MDA-MB-
mice were purchased from Harlan. Triple-negative breast cancer cells (5 x
106,
x BXPC3; 5x10 6 ,
231; ATCC number: HTB-26) or pancreatic carcinoma cells (3.5
MIAPaCa-2) were implanted into right flank of athymic nude mice. Tumor-bearing mice
were randomized in different treatment groups when tumors reached an approximate volume
3 . The mice were treated by intraperitoneal injections with vehicle (0.9% NaCl) or
of 100mm
mouse anti-AxI monoclonal antibodies of the invention alone at 300 tg/injection (twice a
week for 4 consecutive weeks) or with gemcitabine (GEMZAR). Tumor volume was
measured weekly with a caliper. The results for BXPC3 were also expressed by a modified
Kaplan-Meier survival curve, using the time taken for the tumor to reach a pre-defined
. A median delay was defined as the time at which 50% of the mice had
volume of 2,000 mm 3
3 . Anti-hAxI niAb 3E3-E8, but not mAbi,
a tumor reaching the volume of 2,000 mm
decreased tumor growth of MDA-MB-23 1 and pancreatic xenografis (Figure 8A, B, Q.
Modified Kaplan-Meier curve demonstrated a 15-days delay to reach 50% survival when
mice were treated with 3E3E8 antibody, when compared to NaCI-treated mice (Figure 8D).
On another series of experiment, MIAPaca-2 xenografts treated with mAb 3E3-E8 or
irrelevant murine IgGl isotype mAb (Px) were explanted after two mAb treatment injections,
and used for western-blot detection of AxI receptors (anti-Axl mAb, R&D systems) or
GAPDH control protein (anti-GAPDH , Millipore). mAb 3E3-E8 treatment induced a marked
decrease of AxI expression in tumors (Figure 8E).
EXAMPLE 9: THE EPITOPE OF THE MOUSE ANTI-HUMAN AXL
MONOCLONAL ANTIBODY IS A CONFORMATIONAL EPITOPE COMPOSED
OF 2 PEPTIDES, ONE LOCALIZED IN THE FIBRONECTINE 3 DOMAIN 1 AND
ONE IN THE FIBRONECTINE 3 DOMAIN 2 OF HUMAN AXL
To define the epitope structures, limited proteolysis assays of an immobilized antigen-
antibody complex were performed. To map the 3E3-E8 epitope, the hAxl-hFc was affinity
bound to the immobilized 3E3-E8 monoclonal antibody under physiological conditions. A
series of proteolytic enzymatic cleavages (serine protease Trypsine and endoproteinase G1uC)
was then performed to remove hAxl-Fc residues that are unprotected by the 3E3-E8. After
elution, the protected residues, i.e., the 3E3-E8 epitope, were identified based on their
molecular weights, as determined by MALDI-MS analysis of the peptides that were affinity
bound to the immobilized antibody.
The 3E3-E8 monoclonal antibody (250 tg) was coupled to ProMag Magnetics
Microsphere PMC3N (Bangs Laboratories) 1 hour at room temperature according to the
supplier’s procedures. 50 ig of 3E3-E8 microbeads complex were incubated with 50 tg of
the antigen hAxl-hFc (R&D system) and allowed to bind for 90 minutes at 4C. Free antigen
was removed by three washes with buffer. The immune complexe of 3E3-E8 and bAxl-hFc
was digested at 37C with ug of Trypsin or G1uC during 2h15. The supernatant was
0.35 j
separated by centrifugation (2000g, 4C, 3 mm) and discard. The microbeads associated with
3E3-E8 and hAxl-hFc protected residues were washed three times with buffer. Dissociation
was allowed to proceed for 40 min at room temperature using TFA (trifluoroacetic acid)
0.1%. Spectra were obtained by MALDI mass spectrometry (ABSCIEX MALDI 4800 with a
Laser Nd/YAG at 355nm, 200Hz, 20kV for the source of tension, extraction time of 250 ns)
with the sum of 1500 laser shots. The matrix used for the sample was a-cyano
hydroxycinnaminic acid (CHCA) at 5mg/mt. The sequence composition of the antigen hAxi-
hFc (R&D system) and the epitope sequence of the 3E3-E8 identified are shown in the Figure
9. The mouse monoclonal 3E3-E8 antibody binds to a conformational 3D epitope composed
of 2 peptides one positioned in the fibronectine type III domain 1 (sequence: CNLHLVSR)
and one positioned in the fibronectine type III domain 2 (sequence:"VLMDIGLRQEVTLE").
EXAMPLE 10: THE EPITOPE OF THE MOUSE ANTI-HUMAN AXL
MONOCLONAL ANTIBODY IS EXPOSED TO THE ACCESSIBLE SOLVENT
SURFACE AREA AND IS STRUCTURALLY LOCALIZED FAR FROM THE
INTERACTION SITE OF GAS6
The extracellular domain model of the human Axi protein was constructed in 2 steps.
First, the Immuno globulin- like domains (domain I and 2) were extracted from the
crystallographic structure available in the Protein Data Bank under the code 2C5D. This
structure represents an AxIIGas6 complex in which the two immuno globulin- like domains of
the Axi ectodomain are crosslinked by the first laminin G-like domain of Gas6.
Unfortunately, the two fibronectin type III (FN3) domains of Axi have not been crystallized
yet, and therefore needed to be modelized. The model was built by homology modeling using
the 3D structure of FN3 tandem A77-A78 from the A chain of the human titin protein (PDB
id: 3 LPW) as template. After alignment, the sequences of the two proteins share an identity of
22.8 %. Finally, the Immunoglobulin- like domains and the fibronectin type III domains were
linked together between leucine 224 and proline 225 modifying dihedral angles in order to
minimize the steric hindrance between the side chains of the two domains.
The epitope of the mouse anti-Axi antibody 3E3-E8 as well as the Gas6 binding
domains were then identify on this model of the whole ectodomain of human Axi. This model
demonstrates the specific localization of the two surface-localized antigenic sites recognized by
3E3-E8 on Axi (Figure 10). This model demonstrated also that the 3E3-E8 epitope, composed
of the 2 peptides (the first one in the FN3 domain 1 and the second one in the FN3 domain 2
of Axi), is localized far from ligand-binding site (Gas6-binding site which is localized in the
IgG like domain 1) in accordance with the competition studies performed (example 3; Figure
3B).
REFERENCES:
Throughout this application, various references describe the state of the art to which
this invention pertains. The disclosures of these references are hereby incorporated by
reference into the present disclosure.
Claims (17)
1. An antibody having specificity for Ax1, wherein said antibody binds to a conformational epitope of Ax1 comprising the peptide of SEQ ID NO:9 in the FN3 domain 1 of Ax1 and the peptide of SEQ ID NO:10 in the FN3 domain 2 of Axl.
2. The antibody according to claim 1, wherein said antibody is a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO:6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region.
3. The antibody according to claim 1 or 2 wherein the heavy chain variable region of said antibody has the amino acid sequence set forth as SEQ ID NO: 1.
4. The antibody according to claim 1 or 2 wherein the light chain variable region has the amino acid sequence set forth as SEQ ID NO: 5.
5. The antibody according to claim 3 or 4 wherein the heavy chain variable region of said antibody has the amino acid sequence set forth as SEQ ID NO: 1 and the light chain variable region has the amino acid sequence set forth as SEQ ID NO:
6. The monoclonal antibody according to claim 5 which is a chimeric antibody, preferably a chimeric mouse/human antibody.
7. The antibody according to claim 1 or 2 which is a humanized antibody. 10439768
8. A fragment of an antibody according to any one of claims 1 to 7 which is selected from the group consisting of Fv, Fab, F(abâ)2, Fabâ, dsFv, scFv, sc(Fv)2 and diabodies.
9. A nucleic acid sequence encoding an heavy chain or light chain of the antibody according to any one of claims 1 to 7.
10. A vector comprising a nucleic acid according to claim 9.
11. An isolated host cell comprising a nucleic acid according to claim 9 or a vector according to claim 10.
12. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8.
13. The antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8 for use as a drug.
14. Use of an anti-Ax1 antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8 in the manufacture of a medicament for the treatment of cancer.
15. The antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8 for use in the diagnosis of cancer.
16. Use of an anti-Axl antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of human immune disorders, thrombotic diseases, cardiovascular diseases and viral, bacterial, or parasitic infections in a subject in need thereof. 10692443
17. The antibody according to any one of claims 1 to 7 or a fragment thereof according to claim 8 for use in the diagnosis of a disease selected from the group consisting of human immune disorders, thrombotic diseases, cardiovascular diseases and viral, bacterial, or parasitic infections.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305792 | 2011-06-22 | ||
EP11305792.1 | 2011-06-22 | ||
US201161504256P | 2011-07-04 | 2011-07-04 | |
US61/504,256 | 2011-07-04 | ||
PCT/EP2012/062115 WO2012175692A1 (en) | 2011-06-22 | 2012-06-22 | Anti-axl antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618740A NZ618740A (en) | 2015-12-24 |
NZ618740B2 true NZ618740B2 (en) | 2016-03-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2723377B1 (en) | Anti-axl antibodies and uses thereof | |
EP2723376B1 (en) | Anti-axl antibodies and uses thereof | |
KR102101806B1 (en) | Anti-human-her3 antibodies and uses thereof | |
CA2985143C (en) | Anti-human-her3 antibodies and uses thereof | |
JP6449876B2 (en) | Anti-human HER3 antibody that is non-competitive and allosteric for neuregulin and uses thereof | |
US10526415B2 (en) | Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor | |
US20180291098A1 (en) | Anti-nrg1 (heregulin) antibodies and uses thereof | |
NZ618740B2 (en) | Anti-axl antibodies and uses thereof | |
ES2712736T3 (en) | Anti-Axl antibodies and their uses |